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Summary.-Various procedures for immunoprotection in the A-SW mouse SEWA
tumour system were compared. Four types of protector agents were used: polyoma
virus, allogeneic S724 cells, A9/SEWA hybrid cells and xenogeneic STpy cells. Sev-
eral injection schedules were also employed. On the whole, reasonable immuno-
protection was obtained. The results, when allogeneic hybrid or xenogeneic cells
were used, were comparable with those obtained for polyoma virus. This indicates
that the T.A.T.A. of the SEWA tumour had been well conserved. When polyoma
virus alone was used as the protector agent, injection 7 days before the tumour
challenge, or iterative injection, afforded better protection than a single injection on
the day of challenge.
THE AIM of this study was three-fold.
Firstly, we wanted to compare the
immunoprotective effect of allogeneic,
hybrid and xenogeneic cells in the experi-
mental system of A-SW mouse/polyoma
induced tumour cell lines. We have
previously shown that cells of C3H mice
transformed in vitro by polyoma virus
afforded a definite immunoprotection in
AKR mice against a polyoma induced
AKR tumour. The protection by these
allogeneic cells was better than that
afforded by polyoma virus (Favre and
Meyer, 1972).
We also wanted to observe the effect
of the time of injection of the polyoma
virus, used as the protector agent, on the
anti-tumoral protection obtained. Pre-
viously, in a study of the kinetics of
protection by polyoma virus in the AKR
mouse/polyoma tumour system, weshowed
that the best immunoprotection was
obtained when the virus was injected 5
days before the tumour challenge (Favre
et al., 1971).
Finally, we wanted to judge the effect
of a more intense immunization by
repeated injections of polyoma virus. In
the polyoma virus-induced tumour/golden
hamster system, repetition of the viral
injections starting on the day of the
tumour challenge (D-day) had led to
enhancement (Favre, 1972).
MATERIALS AND METHODS
Mice.-Two and one-half month old
syngeneic A-SW mice, bred in our labora-
tories, were used.
Tumour cells.-A solid SEWA line
(Sjogren, Hellstrom and Klein, 1961), trans-
plantable by subcutaneous, dorsal injection
was used. This line was derived from a
subcutaneous, ventral tumour obtained at
the site of injection of ascitic SEWA cells.
Unlike the ascitic SEWA cells which only
grow in vitro in suspension culture, these
cells can be grown on glass. However, they
still carry the neo-antigens characteristic of
polyoma virus (Meyer, Berebbi and Klein,
1974). Wiener et al. (1972) have shown that
these cells are probably hybrid cells between
the SEWA cells and the host cells. This
possible hybrid character would certainly
influence the tumorigenicity of the solid
tumour compared with that of the ascitic
tumour. In our experiments this is of little
importance since all the animals received the
same type of tumour.
Polyoma virus.-A small-plaque variant
of the Toronto strain, produced in secondary
mouse embryo cultures, was used (Dulbecco,
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Allogeneic cells, S724.-The cells were
obtained from a transplantable tumour,
S724, derived from a primary tumour of the
salivary glands in an AKR mouse (Bonneau,
1971).
Hybrid cells, A9/SEEWA.-These hybrid
cells were provided by Professor G. Klein
(Harris et al., 1969).
Xenogenic cells, STy. These cells were
obtained from a transplantable tumour,
STpy derived from aprimary polyoma induced
tumour in a golden hamster (Favre, 1972).
One hundred and twenty mice were
injected with 103 viable SEWA tumour cells
in a 0 5 ml volume at Day D. They were
then separated into 12 series of 10. The
mice were given 0-5 ml subcutaneous, dorsal
injections of either 106 P.F.U. polyoma virus
(Py) or a million viable, allogeneic (S 724)
or hybrid (A9/SEWA) or xenogenic (STpy)
cells, or a combination of polyoma virus and
the aforementioned viable cells. The exact
immunization schedule is shown in the Table.
The mice were examined clinically 3
times a week and autopsied at the end of the
experiment or upon death.
The karyotype of the tumours was deter-
mined and found to be the same as the karyo-
type of the injected cells.
RESULTS
Turnour development
(a) Incidence of tumours.-As is shown
in the Table, the treated groups developed
less tumours than the control groups.
Each series of treated mice were
compared statistically both with the
control series and with all the other series
of treated mice, using the direct method
of comparison of proportion, a derivation
of Fisher's method (Fisher and Yates,
1957).
The probability (P) was calculated by
the following formula:
p(a a'l nl! n9! (a,+ a,)! (n,- n2 -a, -a)!
Sn' n,i al! (nl-al)! a2! (n2-a2)! (n, + n2)!
where a =numeratorofthetwoproportionscompaired,
n- (lenominator of the two proportions compared.
The significance of the results was
thence determined.
Con-pared with the controls, there was
no significant difference for the test series
2 immunized on Day D with polyoma
virus and the test series 7 immunized by
10 consecutive, simultaneous injections
of polyoma virus and allogeneic cells from
Day D. Contrary to this, the differenczw
was either significant, or highly significant,
for all the other series when compared
with the controls.
When the different series were com-
pared one with the other, the followingr
results were obtained.
For the first 4 series which had received
polyoma virus, a significant difference was
shown only between series 1 and series 3,
injected 7 days before the challenge, on
the one hand, and series 2, injected on the
day of challenge, on the other.
For the other series, a significant
difference was observed only between
series 11, injected simultaneously with
polyoma virus and xenogeneic STpy cells
and series 7, injected simultaneously with
polyoma virus and allogeneic S 724 cells.
(b) Time of appearance of the tumour.
The significance ofthe times ofappearance
of the tumours was also assessed. For
statistical purposes, the inverse of the
time of appearance was used in the
calculations. This allows the inclusion
of the non-tumour bearing animals whose
inverse times (1/xo) are zero (Meyer,
Fondarai and Lherisson-Straboni, 1967;
Meyer, Lherisson-Straboni and Fondarai,
1968).
Simple analysis of variance, based on
the comparison of variance (Snedecor's
test) and subsequent calculation of the
F ratios was performed to determine
whether the differences observed between
two or more series were significant.
Values of 9500 or 990o were significant
or highly significant.
The differences between each of the
9 test series and the control series were
found to be significant or highly significant
(see Table) confirming the results of
section (a). Only the differences between
series 2, injected solely with polyoma
virus at Day D and series 7, injected with
polyoma virus and allogeneic cells, and theR. FAVRE, Y. CARCASSONNE AND G. MEYER
TABLE.-Repeated Injections were Performed 3/week, M.W.F.
Inoculum
Polyoma
virus
S 724
A9/SEWA
STpy
Controls
Series no.
1
2
3
4
5
6
7
(+ polyoma
virus)
8
9
(+ polyoma
virus)
No. and time of injections
1 (D-7)
1 (D)
10 from (D-7) to (D+ 14)
10 from (D) to (D+ 21)
10 from (D-7) to (D+ 14)
10 from (D) to (D+ 21)
10 from (D) to (D+ 21)
10 from (D) to (D+ 21)
10 from (D) to (D+ 21)
10 10 from (D) to (D+ 21)
11 10 from (D) to (D+ 21)
(+ polyoma
virus)
12
control series were shown to be non-
significant.
When the test series are compared
one with the other, the difference is signifi-
cant between series 1, having received a
single injection at D-7 and series 4,
having received repeated injections from
Day D. The difference between series 3,
having received repeated injections from
D-7 and series 2, having received a
single injection on the day of challenge,
is highly significant.
The rest of the statistical analysis
afforded no further information.
Frequency of metastases
Post-mortem examination confirmed
the presence of a tumour in 28 animals.
Of these, 14 presented metastases of
which 3 were multiple metastases. Count-
ing these 3 mice, 8 cardiac, 6 pulmonary,
2 pleural, one renal and one para-renal
metastases were observed.
The cardiac metastaseswereall myocar-
diac with neoplasic, intraventricular pro-
liferation in either or both ventricles.
No. of
tumours
1/9 (S)
5/9 (N.S.)
0/10 (H.S.)
2/t0 (S)
2/10 (S)
2/10 (S)
5/10 (N.S.)
Mean of
inverse of
time of
appearance of
tumour
0 004 (H.S.)
0-026 (N.S.)
o (H.S.)
0 005 (H.S.)
0 009 (H.S.)
0 009 (H.S.)
0-011 (N.S.)
Site of metastases
Cardiac
Cardiac
Pulmonary
Cardiac
Cardiac
Pulmonary
Cardiac
Cardiac, pulmonary
2/10 (S) 0-011 (S) Pulmonary
2/10 (S) 0 007 (S) Pleural
2/10 (S) 0 009 (S) Cardiac
Cardiac, pulmonary
Renal
0/10 (H.S.) 0 (H.S.)
7/10 0 039 Pleuro-pulmonary
Pararenal
The pulmonary or pleural metastases were
composed of micronodules, which were
occasionally confluent, particularly in the
lung. The renal metastasis was massive
with a pararenal invasion composed of a
mass of extracapsular, neoplasic cells in
the region of the adrenal gland.
Practically all the organs, i.e. the liver,
spleen, thymus, salivary glands, digestive
tract and the aforementioned organs, with
the exception of the nervous system and
bones, were examined by autopsy. No
organs other than those mentioned above
were ever invaded.
DISCUSSION
The uniformity of the results for the
test series leads us to believe that we can
have confidence in the significant results
obtained. This is true both when the
number of tumour bearing animals per
series was analysed and when the inverse
of the time of appearance of the tumour
was examined.
However, it is possible that by increas-
ing the number of animals in each series
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a significant difference between the second
and ninth series could be obtained. Ten
animals per series were chosen since we
considered this a large enough number for
immunoprotection tests.
We could have also increased the
number of cells used in the immunizing
injection to obtain a better protection.
However, we wanted our experimental
conditions to correspond as closely as
possible with those used in immuno-
therapy treatments in man. We there-
fore chose a million cells, the approximate
number of cells used in treating residual
human illness. We are, nevertheless,
aware that the experimental situation is
not exactly superimposable. For instance
it is difficult to devise an injection
schedule which corresponds with that used
in man. We chose 3 injections a week
without being certain that this was the
optimal timing for immunization.
Further experiments are undoubtedly
necessary to solve these problems. By
varying the number of cells used and the
timing of the injections, immunological
responses ranging from protection to
enhancement might be elicited.
We should also point out that there was
a good conservation of the immuno-
genicity of the SEWA tumour derived
from the ascitic tumour and no loss of
T.A.T.A. for the solid tumour.
The results obtained for the first group
show that the best protection is obtained
when the immunizing injections of poly-
oma virus are given at D-7 rather than
Day D. This confirms the results we
have previously obtained in another
experimental system (Favre et al.,
1971). Repeated injection of polyoma
virus at the dose used apparently enhances
the protection, as shown by the results of
the third series.
Contrary to the results obtained for
polyoma virus, starting the series of
injections of allogeneic S 724 cells at
D-7 did not afford better protection
than starting at Day D.
Allogeneic, hybrid and xenogeneic cells
afforded a protection comparable with
that obtained with polyoma virus. In
the case of the hybrid and xenogeneic
cells, better protection was obtained by
associating these protector agents with
polyoma virus. In the case of the allo-
geneic cells, however, association with the
virus clearly diminished the protective
effect. We find this result inexplicable.
Apparently, it is not an enhancement
since the animals showed fewer tumours
than the control group and these tumours
were slow to appear.
The frequency of metastatic localiza-
tions seemed as great in the immunized
animals as in the controls, but only the
latter presented tumours.
Metastases were observed in 2 out of 7
tumour bearing control animals and 12
out of 21 tumour bearing test animals.
These results cannot be analysed statistic-
ally.
CONCLUSION
The conservation of the T.A.T.A.
in the SEWA tumour allowed us to com-
pare various immunoprotector agents and
various modes of immunoprotection. In
our experimental system, repeated immu-
nization was more efficacious than a single
immunization on the day of challenge.
Allogeneic S 724 cells or hybrid A9/
SEWA cells or xenogeneic STpy cells
afforded a protection comparable with
that of polyoma virus.
Inthelightoftheoccasionalunexpected
result observed, it would probably be more
profitable to conduct this type ofimmuno-
protection or immunotherapy experiment
simultaneously with an in vitro lympho-
toxicity or serotoxicity experiment (Taka-
sugi and Klein, 1970).
We are grateful to Professor H.
Bonneau for the pathological examina-
tions and for his helpful advice.
We thank Mrs C. Lipcey for her help
with the manuscript and Mrs M. Mouren
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